KIMBERLY ANN LENKEIT

Allopathic & Osteopathic Physicians|Family Medicine KANSAS CITY, MO NPI 1306337159

General Payments — all program years on this page

$1,052.33

  • Category: General Payments
  • Program years: PY2022–2024
  • Record count: 53
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $362.00 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $362.0020

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Novo Nordisk AS $143.229
ABBVIE INC. $111.215
Abbott Laboratories $40.282
GlaxoSmithKline, LLC. $35.832
BOSTON SCIENTIFIC CORPORATION $17.491
Acerta Pharma LLC $13.971

By program year

Program yearAmountRecords
2022 $225.479
2023 $464.8624
2024 $362.0020

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1092573697 Boston Scientific Corporation $17.49 11/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096584297 Novo Nordisk Inc $16.86 03/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096870271 Novo Nordisk Inc $11.67 10/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096887570 Novo Nordisk Inc $17.04 04/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096907943 Novo Nordisk Inc $20.62 06/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096941902 Novo Nordisk Inc $15.81 07/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097249219 Novo Nordisk Inc $16.02 01/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097394362 Novo Nordisk Inc $20.56 09/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097504649 Novo Nordisk Inc $14.42 07/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097634445 Novo Nordisk Inc $10.22 06/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104161620 ABBVIE INC. $19.57 03/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104161622 ABBVIE INC. $29.72 05/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104161624 ABBVIE INC. $21.22 06/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104161626 ABBVIE INC. $25.21 07/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104161628 ABBVIE INC. $15.49 10/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105775818 AstraZeneca Pharmaceuticals LP $13.97 07/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116331971 GlaxoSmithKline, LLC. $14.80 01/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116591171 GlaxoSmithKline, LLC. $21.03 07/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1124975384 Abbott Laboratories $17.72 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1124975388 Abbott Laboratories $22.56 12/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.